ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-OR01

Clonal Hematopoiesis of Indeterminate Potential Is Associated With a Higher Risk of Incident AKI

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology‚ Risk Factors‚ and Prevention

Authors

  • Vlasschaert, Caitlyn, Queen's University, Kingston, Ontario, Canada
  • Bick, Alexander, Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Rauh, Michael J., Queen's University, Kingston, Ontario, Canada
  • Lanktree, Matthew B., McMaster University, Hamilton, Ontario, Canada
  • Grams, Morgan, Johns Hopkins University, Baltimore, Maryland, United States
  • Psaty, Bruce M., University of Washington, Seattle, Washington, United States
  • Kottgen, Anna, Albert-Ludwigs-Universitat Freiburg, Freiburg im Breisgau, Baden-Württemberg, Germany
  • Franceschini, Nora, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Kramer, Holly J., Loyola University Chicago, Chicago, Illinois, United States
  • Kestenbaum, Bryan R., University of Washington, Seattle, Washington, United States
  • Robinson-Cohen, Cassianne, Vanderbilt University Medical Center, Nashville, Tennessee, United States

Group or Team Name

  • TOPMed Kidney Working Group
Background

Clonal hematopoiesis of indeterminate potential (CHIP) is a common, age-related process wherein an acquired driver mutation in a hematopoietic stem cell produces a resilient clonal leukocyte population with dysregulated inflammatory signaling. The presence of CHIP has been associated with the progression of chronic kidney disease. We tested whether CHIP is a novel risk factor for acute kidney injury (AKI) in two community-based cohorts.

Methods

We evaluated participants from the Atherosclerosis Risk in Community (ARIC; N = 10,570) and Cardiovascular Health Study (CHS; N = 2,792). We identified somatic DNA mutations in peripheral leukocytes that met established criteria for CHIP using whole exome and whole genome data. AKI events were previously ascertained in both cohorts based on hospitalization codes with additional validation by manual chart review in CHS. We used proportional hazards regression to test associations of CHIP with AKI after adjustment for relevant confounders.

Results

CHIP was identified in 7.6% of ARIC participants (median age: 58) and 14.5% of CHS participants (median age: 72). The incidence rate of AKI was higher among persons with CHIP in both cohorts: 12.6 vs. 10.4 events per 1000 person-years in ARIC and 6.6 vs. 4.4 events per 1000 person-years in CHS. In a fixed-effects meta-analysis adjusted for age, age2, sex, and baseline eGFR, the presence of CHIP was associated with an estimated 18% greater risk of AKI (HR 1.18, 95% CI: 1.02 – 1.37). The risk for AKI was greatest for mutations in driver genes other than DNMT3A (non-DNMT3A CHIP; HR 1.29, 95% CI: 1.07 – 1.55).

Conclusion

CHIP is associated with a greater risk of incident AKI in two large community-based cohorts. Non-DNMT3A CHIP mutations demonstrate the strongest associations with incident AKI. CHIP may therefore be a novel risk factor for AKI that could partially explain the strong age dependency of this condition. Future studies will elucidate which subtypes of CHIP pose the highest risk of kidney sequelae and in which scenarios emerging treatments for CHIP would be beneficial.

Funding

  • Other NIH Support